- Home
- BIIB vs EIX Comparison
BIIB vs EIX Comparison
Compare BIIB & EIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- EIX
- Stock Information
- Founded
- BIIB 1978
- EIX 1886
- Country
- BIIB United States
- EIX United States
- Employees
- BIIB N/A
- EIX N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- EIX Electric Utilities: Central
- Sector
- BIIB Health Care
- EIX Utilities
- Exchange
- BIIB Nasdaq
- EIX Nasdaq
- Market Cap
- BIIB 24.2B
- EIX 21.3B
- IPO Year
- BIIB 1991
- EIX N/A
- Fundamental
- Price
- BIIB $168.52
- EIX $58.99
- Analyst Decision
- BIIB Buy
- EIX Hold
- Analyst Count
- BIIB 24
- EIX 12
- Target Price
- BIIB $174.62
- EIX $65.27
- AVG Volume (30 Days)
- BIIB 1.8M
- EIX 2.8M
- Earning Date
- BIIB 10-30-2025
- EIX 10-28-2025
- Dividend Yield
- BIIB N/A
- EIX 5.64%
- EPS Growth
- BIIB N/A
- EIX 123.49
- EPS
- BIIB 10.97
- EIX 7.64
- Revenue
- BIIB $10,065,900,000.00
- EIX $18,088,000,000.00
- Revenue This Year
- BIIB $2.97
- EIX $7.30
- Revenue Next Year
- BIIB N/A
- EIX $2.70
- P/E Ratio
- BIIB $15.27
- EIX $7.69
- Revenue Growth
- BIIB 4.77
- EIX 4.43
- 52 Week Low
- BIIB $110.04
- EIX $47.73
- 52 Week High
- BIIB $175.86
- EIX $88.65
- Technical
- Relative Strength Index (RSI)
- BIIB 74.64
- EIX 63.77
- Support Level
- BIIB $151.83
- EIX $56.21
- Resistance Level
- BIIB $157.79
- EIX $59.34
- Average True Range (ATR)
- BIIB 5.59
- EIX 1.10
- MACD
- BIIB 1.37
- EIX 0.26
- Stochastic Oscillator
- BIIB 95.37
- EIX 91.70
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
About EIX Edison International
Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.